טוען...
Drug therapy of overactive bladder - What is coming next?
After the approval and introduction of mirabegron, tadalafil, and botulinum toxin A for treatment of lower urinary tract symptoms/overactive bladder, focus of interest has been on their place in therapy versus the previous gold standard, antimuscarinics. However, since these agents also have limitat...
שמור ב:
| הוצא לאור ב: | Korean J Urol |
|---|---|
| מחבר ראשי: | |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The Korean Urological Association
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4610893/ https://ncbi.nlm.nih.gov/pubmed/26495067 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4111/kju.2015.56.10.673 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|